Go Pro

Relmada Therapeutics (RLMD) News Today

Relmada Therapeutics logo
$4.58 -0.05 (-1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$4.58 0.00 (-0.11%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Relmada Therapeutics Latest News

Relmada (RLMD) Q2 2026 Earnings Call Transcript
HC Wainwright Brokers Increase Earnings Estimates for RLMD
Equities Analysts Issue Forecasts for RLMD Q3 Earnings
Relmada Therapeutics Q2 Earnings Call Highlights
Relmada Therapeutics Inc

Relmada Therapeutics Media Mentions By Week

Relmada Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RLMD
News Sentiment

0.51

0.66

Average
Healthcare
News Sentiment

Relmada Therapeutics News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RLMD Articles
This Week

1

3

RLMD Articles
Average Week

Relmada Therapeutics Trends on MarketBeat

This week vs. last week
New Followers
1
-50%
Searches
1
-50%
Page Views
1,840
+2%
Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Relmada Therapeutics dated 8/17/2026.
From Our Partners